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Goal in pharmaceutical research is achievement of necessary drug concentrations in the target organ, effective treatment with safe delivery of
genetic agents, while sparing normal tissue and minimizing side effects. A new “BioShuttle”-delivery system harbouring a cathepsin B cutting
site, a nuclear address sequence and a functional peptide was developed and tumor cells were treated. Transport and subcellular activation were
determined by confocal laser scanning microscopy permitting the conclusion: BioShuttle-conjugates prove as efficient tools for genetic
interventions by selective and topical activation of therapeutic peptide precursors by enzymatic cleavage. As shown here for glioma cells and the
cathepsin B cleavable site, living cells can be treated with high specificity and selectivity for diagnostic and therapeutic purposes.
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The major goal in cancer therapy is to increase the therapeutic
ratio by eliminating the disease while minimizing toxicity to
normal tissues. Classical drugs enter the cells mainly by diffusion,
but the lack of specificity requires high application doses accom-
paniedwith increased side effects resulting in a breakdown during
therapy. Modern drugs, like DNA-derivatives, are characterized
by specificity and sensitivity. However their transport across
biological membranes is very poor and needs suitable carrier
systems [1]. Delivery of genetic agents into the host cell has been
a main strategy, carried out by direct DNA injection, encapsu-
lation into liposomes or other artificial encapsulation strategies
have been applied with different success [2]. Drug delivery sys-
tems such as lipid-, polymer- and peptide-based particles can be
designed to improve the pharmacological and therapeutic prop-
erties of drugs administered parenterally [3]. In this context, a
further open question is the release of the transported agent at its
target site. One possible answer is the use of the modular, peptide-⁎ Corresponding author. Tel.: +49 6221 42 2847; fax: +49 6221 42 2846.
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cellular targeting to subcellular components using cell immanent
mechanisms [4]. In neoplastic tissues the content of cathepsin B is
increased manifold in contrast to normal cells where it is hardly
detectable [5,6]. In order to distinguish between tumor and nor-
mal cells we used a BioShuttle transporter for peptide-based drugs
which became activated after digestion of a Cathepsin B Cleav-
able Spacer (BioShuttle-CBCS-conjugate).
2. Material and methods
2.1. Synthesis and purification of the BioShuttle-CBCS-conjugates
For solid phase synthesis of the FITCVKRKKKP-KD-GFGRK(Dabcyl)-RQIK
IWFQNRRM-KWKK [BioShuttle-CBCSD-complex (#5293)] and
FITCVKR
KKKP-KL-GFGRK-(Dabcyl)-RQIKIWFQNRRMKWKK [BioShuttle-CBCSL-
complex (#5294)] we employed the Fmoc (9-fluorenylmethyl-oxycarbonyl) meth-
odology [7,8] in a fully automatedmultiple synthesizer (Syro II fromMultiSyntech
Germany). As coupling agent 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluro-
nium hexafluorophosphate (HBTU) was used. The following side chain protecting
groups were employed: Boc (tert-butyloxycarbonyl) for Lys and Trp, Trityl
(triphenylmethane) for Gln and Asn and Pbf (2,2,4,6,7-Pentamethyldihydroben-
zofurane-5-sulfonyl) for Arg. Fmoc-Lys(Dabcyl) was purchased from Merck Bio-
sciences GmbH, Germany. The synthesized peptides were cleaved and deprotected
Fig. 1. The HPLC peak reports the D-form of BioShuttle–CBCSD-complex (left site) and the L-form of the BioShuttle–CBCSL-complex (right site). The estimated
substance purity is 99.3% with the retention time of 14.6 min (#5293) and 100% and with 15.5 min (#5294) (upper part). The lower part represents the corresponding
mass spectra. Abscissa: HPLC: Minutes, Ordinate: HPLC: milliVolt Absorption Unit, MS: ratio masse charge (m/z), Ion Intensity (a. I.).
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isopropylsilane, and 2%water (v/v/v/) for 2.5 h at room temperature. The products
were precipitated in ether. The crudematerial was purified by preparative HPLCon
aKromasil 100–10C18μm reverse phase column (30×250mm) using an eluent of
0.1% trifluoroacetic acid inwater (A) and 80% acetonitrile inwater (B) The peptide
was eluted with a successive linear gradient of 10%B to 80%B in 30 min at a flow
rate of 23 ml/min. The fractions corresponding to the purified protein were
lyophilized. The purified material was characterized with analytical HPLC and
matrix assisted laser desorption mass spectrometry (MALDI-MS) (Fig. 1).
2.2. Cathepsin B in vitro assay
In order to proof the cathepsin B specific cleavage we incubated 10 Units
(5 μg enzyme, Sigma-Aldrich, Germany) with 100 μg peptide for 60 min 40 °CFig. 2. CLSM exposures of C6 glioblastoma cells (lines A, C and D) and HeLa c
fluorescence light, whereas the right column represents the corresponding DIC-pictu
treated with BioShuttle harbouring the cleavable L-form of the cathepsin recognit
BioShuttle with the L-form of the cathepsin B cleavage site (KGFGRK). Line C sho
form of the cathepsin B recognition site [BioShuttle–CBCSD-complex]. The lower ro
cathepsin B proinhibitor CA-074 methyl ester after 24 h of incubation. The bars repin 20 mM sodium acetate buffer at pH 6 in a total volume of 500 μl. The
BioShuttle–CBCSL-complex was enzymatically digested and furthermore
separated by HPLC. The chromatography was carried out with a Kromasil
KR 100–10C18 column, the sample was eluted with a gradient consisting of
buffer A 0.1% TFA in water and eluent B 0.1% TFA in water/acetonitrile (20/
80). The gradient was applied for 30 min from 5% to 80% B. The probe was
detected at 210 nm wavelength. Using the MALDI-MS, the molecular
identification of the metabolites was achieved.
2.3. Cell culture and experimental accomplishment
C6 glioblastoma and HeLa cells (DKFZ tumor bank) were cultivated in
minimal essential medium supplemented with 10% Fetal Bovine Serum, 2 mM
glutamine, 100 U×ml−1 penicillin, 100 μg×ml−1 streptomycin (Sigma-Aldrich).ervix carcinoma cells (line B) are shown. The left column reveals the emitted
res of the cells (differential interference contrast). Line A shows C6 glioma cells
ion site [BioShuttle–CBCSL-complex]. Line B shows HeLa cells treated with
ws C6 glioblastoma cells treated with BioShuttle containing the uncleavable D-
w (line D) demonstrates a slight fluorescence signal in C6 cells treated with die
resent 50 μm.
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glioblastoma cell line and HeLa cells (5×105) were incubated for 24 h in quad-
riperm®plus (Heraeus) containing sterile glass coverslips. After twowash-cycleswithMEM, the cells were incubated with BioShuttle–CBCSL-complex (10 μM).
To investigate the stereochemical specificity of cathepsin B, the corresponding
D-form of the cathepsin cleavable spacer was incubated as a further control with
Fig. 3. (A) Shows the HPLC diagrams of the cathepsin B in vitro assay. The
upper part represents the graphic of the HPLC procedure without enzyme. The
peak (19 min) corresponds to the undigested BioShuttle–CBCSL-complex. The
lower part shows the resulting peaks 1 and 2 (11 and 12 min) after 60 min
enzymatic digest. The peak of the BioShuttle–CBCSL-complex nearly
disappeared. Both diagrams exhibit two identical injection peaks (left, in
front). Abscissa: HPLC: Minutes, Ordinate: HPLC: milliVolt Absorption Unit.
(B) The right part of panel B represents the corresponding MS spectra of the
peaks 1 and 2 containing both metabolites. The MWs 1371.10 and 2663.18
according to the peaks 1 and 2 respectively are demonstrated. MS: ratio masse
charge (m/z), Ion Intensity (a. I.).
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30 min. The culture medium was removed to enable microscopic studies. Cells
were washed twice and were finally embedded in Moviol®.
2.4. Confocal imaging
The intracellular distribution of the BioShuttle–CBCSL-complex and Bio-
Shuttle–CBCSD-complex in non fixed C6 and HeLa cells was verified by a
Zeiss confocal laser scanning microscope (LSM 510-Meta). For excitation, we
used the laser lines at 488 nm and 543 nm wavelengths and the corresponding
barrier filters for emission. Simultaneously with the fluorescence images, also
images in differential interference contrast (DIC) were taken. Parameters of the
image acquisition were adapted to show the signal intensities in accordance with
the visual microscopic image aspect.
3. Results and discussion
The degradation of the extracellular matrix protein, a pre-
requisite for the invasive phenotype in glioma cells, is associated
with the increased expression levels of proteases like cathepsins
which are associated with increased motility and the potential to
hydrolyse macromolecular components of the extracellular ma-
trix [9]. Increased expression and activity of the lysosomal cys-
teine protease cathepsin B have been observed in different
tumors, especially including prostate, breast, and gastrointesti-
nal cancers [10]. Increased cathepsin B expression and high
activity of the corresponding gene product are associated with
tumor malignancy in brain tumors [11]. The correlation between
the amounts of cathepsin B mRNA, protein, enzymatic activity
and tumor progression could serves as an evidence for the in-
volvement of cathepsin B in the tumor pathology [6].
To proof the elevated levels of cathepsin B in the C6 glioma
tumor cells, they were treated with BioShuttle–CBCSL-complex
showing a fluorescence signal in the nuclei (Fig. 2, line A, left
picture). This demonstrates the enzymatic cleavage in the cyto-
plasm liberating the nuclear localization signal (NLS) and move-
ment of the separated sequence into the nuclei. By that we were
able to distinguish between cathepsin B high level expression and
background expression in HeLa cells. In HeLa cells, the NLS
peptide could not be liberated by cathepsin B cleavage and there-
fore did not show a significant nuclear fluorescence (line B). In
order to determine the enzymatic substrate stereospecificity (of
cathepsin B), we constructed a BioShuttle–CBCS-conjugate with
one single amino acid (lysine) in the enzyme cleavage site in D-
conformation as opposed to the L-compound. With the construct
we could demonstrate that this sterical property protects the Bio-
Shuttle–CBCSD-complex against enzymatic digest (Fig. 2, line C).
Fig. 2D shows that the inactivation of cathepsin B could be
achieved by the highly selective cathepsin B proinhibitor CA-
074 methyl ester [12]. To test whether CA-074 methyl ester has
the capacity to inactivate cathepsin B, C6 cells were incubated
for 24 h with the proinhibitor (10 μm).
This membrane-permeable compound was applied to the cell
culture medium where its intracellularly converted to CA-074
by endogenous esterases [13]. The picture shows that the ca-
thepsin B activity was strongly reduced and cleavable Bio-
Shuttle–CBCSL-complex remained extensively undigested by
the enzyme (Fig. 2, line D). There is only a slight fluorescence
signal in the cytosol of C6 cells treated with the cathepsin B
610 R. Pipkorn et al. / Biochimica et Biophysica Acta 1758 (2006) 606–610proinhibitor CA-074 methyl ester (Sigma-Aldrich), presumably
because the NLS was inaccessible for the importin-mediated
nuclear transport machinery. An in vitro assay using the puri-
fied cathepsin B enzyme and the substrate with the enzy-
matic recognition site could demonstrate the effect as shown in
Fig. 3.
Fig. 3A (upper part) represents the peak of the undigested
BioShuttle–CBCSL-complex. After enzyme treatment, the
lower part of the Fig. 3A exhibits two additional peaks which
indicate the enzymatic cleavage products of the BioShuttle–
CBCSL-complex after 60 min digest. The substantial content of
the peaks was determined by mass spectrometry methods which
resulted in the relevant molecular weights. The peak 1 cor-
responds to the metabolite 1 (FITC-VKRKKKPK-COOH, MW
calculated: 1371.71) and the peak 2 correlates to metabolite 2
(GFGRK(Dabcyl)RQIKIWFQNRRMKWKK, MW calculated:
2663.50) (Fig. 3B).
The presented delivery platform has the potential to transport
highly efficient, highly specific high molecular weight drugs.
These will be liberated and activated at their targets by the in-
trinsic mechanisms of cells.
The stable residence time of several hours of the BioShuttle–
CBCSL-complex in the cytoplasm allows administration with-
out fear for unwanted agent-activation in the blood circuit and
the surrounding tissue.
The use of the BioShuttle-mediated delivery systems for
agents with high molar mass like peptide- or nucleic acid-mole-
cules is an efficient new two-step approach in the field of diag-
nostic and therapy of genetically based diseases like cancer. It
uses the cell's own mechanisms which are inactive in normal
cells and tissues but highly activated in neoplastic target cells.
As future aspects, we plan to use such specific peptide spac-
ers, designed to be biorecognizable by intracellular enzymes, as
site-specific activators. As an auspicious approach to increase
the cell-specific release of diagnostics for intravital imaging as
well as for therapy, we can apply highly reactive chemother-
apeutics and peptide- or nucleic acid-based molecules. This
study proves the concept of the BioShuttle–CBCSL-complex
strategy but further optimization is necessary.Acknowledgements
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